Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers

✍ Scribed by John Davis; Frances Hackman; Marie-Noella Ndongo; HengWee Choo; Drew Lewis; Margaret Tawadrous; James Goodrich; Grant Langdon

• Book ID: 113544301
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 90 KB
• Volume: 32
• Category: Article
• ISSN: 0149-2918
• DOI: 10.1016/j.clinthera.2010.10.007